Jpmorgan Chase & Co »

Enliven Therapeutics shares owned by Jpmorgan Chase & Co

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by Jpmorgan Chase & Co from 13F filings

Historical chart of Jpmorgan Chase & Co investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by Jpmorgan Chase & Co consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by Jpmorgan Chase & Co

Quarter filed Position value Share count Share price at filing
2024-09-30 $531k 21k 25.54
2024-06-30 $486k 21k 23.37
2024-03-31 $323k 18k 17.59
2023-12-31 $332k 24k 13.84
2023-09-30 $362k 27k 13.66
2023-06-30 $626k 31k 20.41
2023-03-31 $2.0k 94 21.28